S

AN FRANCISCO — Northern California is in for torrential rains this week, but water won’t be the only thing flooding the streets here.

The annual J.P. Morgan Healthcare Conference starts today, a four-day crush of crowded hallway conversations, hotel lobby meetings, and open-bar parties that will bring more than 9,000 biotech insiders to Union Square — though more than a few were delayed by the winter storms that socked the East Coast.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • ” Whether any of it will meaningfully impact the market – much less impact patients – remains to be seen ” . Big Pharma always puts the $ ahead of the patient. Look how little compassionate use they give – even for drugs they are so sure of that they have asked for early approval from the FDA. They see dying pt.’s as ” investment risks ” . As they throw even ” subdued ” parties ( no private Cirque du Soleil performance this yr. ?) ; They should be reminded that they chose to be in the field of developing potentially life – saving medicines – not some jazzy new smart phone. I am a Pt. Rights Activist and we want respect – without our sacrifice – none of these drugs get developed. We want compassionate use reform – the 21st Century Cures Act hardly mentions it . It requires co.’s to ” post a policy ” , while 3 of the original 4 compassionate use reform initiatives were dropped from the final bill . Because no one speaks for the ” terminally ill “

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X